Similar articles

• Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation.

  Winkler M, Ringe B, Jost U, Gubernatis G, Pichlmayr R. Winkler M, et al. Transplant Proc. 1993 Aug;25(4):2688-90. Transplant Proc. 1993. PMID: 7689277 Clinical Trial. No abstract available.
• FK 506 treatment of intractable rejection after liver transplantation.

  Jost U, Winkler M, Ringe B, Rodeck B, Pichlmayr R. Jost U, et al. Transplant Proc. 1993 Aug;25(4):2686-7. Transplant Proc. 1993. PMID: 7689276 No abstract available.
• Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients.

  Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Wahlstrom HE, Sanchez-Urdazpal L, Richards T, Crotty P, Beaver S, et al. Porayko MK, et al. Transplant Proc. 1993 Feb;25(1 Pt 1):665-8. Transplant Proc. 1993. PMID: 7679835 Clinical Trial. No abstract available.
• In vitro assessment of FK 506 immunosuppressive activity in transplant patients.

  Zeevi A, Venkataramanan R, Warty V, Eiras G, Woan M, Abu-Elmagd K, Alessiani M, Jain A, Demetris AJ, Zerbe T, et al. Zeevi A, et al. Transplant Proc. 1991 Dec;23(6):2897-9. Transplant Proc. 1991. PMID: 1721307 Free PMC article. Review. No abstract available.
• Adverse effects associated with the use of FK 506.

  Fung JJ, Alessiani M, Abu-Elmagd K, Todo S, Shapiro R, Tzakis A, Van Thiel D, Armitage J, Jain A, McCauley J, et al. Fung JJ, et al. Transplant Proc. 1991 Dec;23(6):3105-8. Transplant Proc. 1991. PMID: 1721372 Free PMC article. Review. No abstract available.